Omeros is approaching a pivotal FDA decision on narsoplimab for TA-TMA. Here’s why this binary event could be a major market mover.

Incyte’s Opzelura faces a key FDA PDUFA decision on Sept 19, 2025 for pediatric atopic dermatitis. Here’s why approval could boost $INCY stock.

The FDA approved a subcutaneous version of Leqembi